Sarah Gheuens - Jul 1, 2025 Form 4 Insider Report for AGIOS PHARMACEUTICALS, INC. (AGIO)

Role
Chief Medical Officer
Signature
/s/ William Cook, as attorney-in-fact for Sarah Gheuens
Stock symbol
AGIO
Transactions as of
Jul 1, 2025
Transactions value $
-$139,789
Form type
4
Date filed
7/3/2025, 04:01 PM
Previous filing
Jun 26, 2025
Next filing
Jul 11, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Gheuens Sarah Chief Medical Officer 88 SIDNEY STREET, CAMBRIDGE /s/ William Cook, as attorney-in-fact for Sarah Gheuens 2025-07-03 0001881190

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AGIO Common stock Options Exercise $0 +8.37K +14.69% $0.00 65.4K Jul 1, 2025 Direct
transaction AGIO Common stock Sale -$140K -4.09K -6.26% $34.17 61.3K Jul 1, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AGIO Restricted stock units Options Exercise $0 -8.37K -50% $0.00 8.38K Jul 1, 2025 Common stock 8.37K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's restricted share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated July 1, 2023.
F2 Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F3 The restricted stock units were granted on July 1, 2023. Beginning on July 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments.